Presentation is loading. Please wait.

Presentation is loading. Please wait.

Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic.

Published byAnikó Illésné Modified over 5 years ago

Similar presentations

Presentation on theme: "Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic."— Presentation transcript:

1 Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models by Mohamed L. Sorror, Barry E. Storer, Mahmoud Elsawy, Amir T. Fathi, Andrew M. Brunner, Aaron T. Gerds, Mikkael A. Sekeres, Sudipto Mukherjee, Bruno C. Medeiros, Eunice S. Wang, Pankit Vachhani, Paul J Shami, Esteban Peña, Shylo Wardyn, Jenny Whitten, Rachelle Moore, Pamela S. Becker, Jeannine McCune, Stephanie J. Lee, Brenda M. Sandmaier, Frederick R. Appelbaum, and Elihu H. Estey Blood Volume 128(22): December 2, 2016 ©2016 by American Society of Hematology

2 Regimen intensity per pt age groups.
Mohamed L. Sorror et al. Blood 2016;128:216 ©2016 by American Society of Hematology

3 Comparisons of hazard ratios (HR) and 2-year rates of survival between intensive and non-intensive initial therapies. Comparisons of hazard ratios (HR) and 2-year rates of survival between intensive and non-intensive initial therapies Mohamed L. Sorror et al. Blood 2016;128:216 ©2016 by American Society of Hematology

4 Intensive versus non-intensive therapies among pts aged 70-79 years with AML.
Mohamed L. Sorror et al. Blood 2016;128:216 ©2016 by American Society of Hematology

Download ppt "Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic."

Similar presentations

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia by Je-Hwan Lee, Young-Don Joo, Hawk.

A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia by Je-Hwan Lee, Young-Don Joo, Hawk.
Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,

Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)1   CC-486 (Oral.

Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)1   CC-486 (Oral.
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia.

Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia.
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
TCR-MHC-peptide(s): in vivo veritas

TCR-MHC-peptide(s): in vivo veritas
Megan Othus, Frederick R. Appelbaum, Stephen H. Petersdorf, Kenneth J

Megan Othus, Frederick R. Appelbaum, Stephen H. Petersdorf, Kenneth J
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Gupta V, Tallman MS, Weisdorf DJ

Gupta V, Tallman MS, Weisdorf DJ
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11):3909-3918 June 1, 1997 ©1997.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Similar presentations

Ads by Google